DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Ecotrin (Aspirin Enteric Coated) - Indications and Dosage

 
 



INDICATIONS AND USAGE

Vascular Indications (Ischemic Stroke, TIA, Acute MI, Prevention of Recurrent MI, Unstable Angina Pectoris, and Chronic Stable Angina Pectoris): Aspirin is indicated to: (1) Reduce the combined risk of death and nonfatal stroke in patients who have had ischemic stroke or transient ischemia of the brain due to fibrin platelet emboli, (2) reduce the risk of vascular mortality in patients with a suspected acute MI, (3) reduce the combined risk of death and nonfatal MI in patients with a previous MI or unstable angina pectoris, and (4) reduce the combined risk of MI and sudden death in patients with chronic stable angina pectoris.

Revascularization Procedures (Coronary Artery Bypass Graft (CABG), Percutaneous Transluminal Coronary Angioplasty (PTCA), and Carotid Endarterectomy): Aspirin is indicated in patients who have undergone revascularization procedures (i.e., CABG, PTCA, or carotid endarterectomy) when there is a preexisting condition for which aspirin is already indicated.

Rheumatologic Disease Indications (Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Spondyloarthropathies, Osteoarthritis, and the Arthritis and Pleurisy of Systemic Lupus Erythematosus (SLE)): Aspirin is indicated for the relief of the signs and symptoms of rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, spondyloarthropathies, and arthritis and pleurisy associated with SLE.

DOSAGE AND ADMINISTRATION

Each dose of aspirin should be taken with a full glass of water unless patient is fluid restricted. Anti-inflammatory and analgesic dosages should be individualized. When aspirin is used in high doses, the development of tinnitus may be used as a clinical sign of elevated plasma salicylate levels except in patients with high frequency hearing loss.

Ischemic Stroke and TIA:   50-325 mg once a day. Continue therapy indefinitely.

Suspected Acute MI:   The initial dose of 160-162.5 mg is administered as soon as an MI is suspected. The maintenance dose of 160-162.5 mg a day is continued for 30 days post infarction. After 30 days, consider further therapy based on dosage and administration for prevention of recurrent MI.

Prevention of Recurrent MI:   75-325 mg once a day. Continue therapy indefinitely.

Unstable Angina Pectoris:   75-325 mg once a day. Continue therapy indefinitely.

Chronic Stable Angina Pectoris:   75-325 mg once a day. Continue therapy indefinitely.

CABG:   325 mg daily starting 6 hours post-procedure. Continue therapy for 1 year post-procedure.

PTCA:   The initial dose of 325 mg should be given 2 hours pre-surgery. Maintenance dose is 160-325 mg daily. Continue therapy indefinitely.

Carotid Endarterectomy:   Doses of 80 mg once daily to 650 mg twice daily, started presurgery, are recommended. Continue therapy indefinitely.

Rheumatoid Arthritis:   The initial dose is 3 g a day in divided doses. Increase as needed for anti-inflammatory efficacy with target plasma salicylate levels of 150-300 mcg/mL. At high doses (i.e., plasma levels of greater than 200 mg/mL), the incidence of toxicity increases.

Juvenile Rheumatoid Arthritis:   Initial dose is 90-130 mg/kg/day in divided doses. Increase as needed for anti-inflammatory efficacy with target plasma salicylate levels of 150-300 mcg/mL. At high doses (i.e., plasma levels of greater than 200 mg/mL), the incidence of toxicity increases.

Spondyloarthropathies:   Up to 4 g per day in divided doses.

Osteoarthritis:   Up to 3 g per day in divided doses.

Arthritis and Pleurisy of SLE:   The initial dose is 3 g a day in divided doses. Increase as needed for anti-inflammatory efficacy with target plasma salicylate levels of 150-300 mcg/mL. At high doses (i.e., plasma levels of greater than 200 mg/mL), the incidence of toxicity increases.

HOW SUPPLIED

81 mg convex orange film coated tablet with ECOTRIN LOW printed in black ink on one side of the tablet. Available as follows

NDC 0108-0117-82 Bottle of 36 tablets

NDC 0108-0117-83 Bottle of 120 tablets

325 mg convex orange film coated tablet with ECOTRIN REG printed in black ink on one side of the tablet. Available as follows:

NDC 0108-0014-26 Bottle of 100 tablets

NDC 0108-0014-29 Bottle of 250 tablets

500 mg convex orange film coated tablet with ECOTRIN MAX printed in black ink on one side of the tablet. Available as follows:

NDC 0108-0016-23 Bottle of 60 tablets

NDC 0108-0016-27 Bottle of 150 tablets

Store in a tight container at 25°C (77° F); excursions permitted to 15-30° C (59-86° F).

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017